The genus Aspergillus is vast—453 species are currently recognized—and its spores are everywhere, floating in both indoor and outdoor air. Most people inhale them daily without consequence. But for the immunocompromised—transplant recipients, chemotherapy patients, those on biologic immunosuppressants, or individuals recently infected with SARS-CoV-2 or influenza—these airborne conidia can trigger anything from allergic bronchopulmonary aspergillosis to invasive pulmonary aspergillosis, a condition with staggeringly high mortality. Among the culprits, Aspergillus fumigatus dominates, causing roughly 70 to 80 percent of invasive cases and earning recognition from the World Health Organization as a critical-priority fungal pathogen. A. flavus, notorious for its aflatoxin production and predilection for warm climates, accounts for another 15 to 20 percent, while A. niger, though less frequently invasive, is gaining clinical relevance.

Diagnosing aspergillosis has long been an imperfect science. Clinicians rely on serological biomarkers such as 1,3-β-D-glucan and galactomannan, alongside culture, but these approaches suffer from nonspecificity or outright failure to detect the etiological agent. PCR-based methods—qPCR, multiplex PCR, nested PCR, droplet digital PCR, even next-generation sequencing—have emerged as powerful alternatives, yet each carries its own baggage: high cost, technical complexity, difficulty distinguishing colonization from true infection, and limited accessibility in developing countries where the burden of fungal disease is often greatest.

Enter SCAR markers—Sequence Characterized Amplified Region markers—a technology that converts the messy, reproducible-but-hard-to-interpret bands of RAPD-PCR (Random Amplified Polymorphic DNA) into clean, species-specific primer pairs. The approach is elegant in its simplicity: researchers run RAPD-PCR with arbitrary primers, identify a band unique to the target organism, clone and sequence it, then design primers that amplify only that sequence. The result is a diagnostic assay that is fast, cheap, and easy to interpret—qualities sorely needed in settings where sophisticated molecular infrastructure is scarce.

Castro-Fuentes and colleagues at the Universidad Nacional Autónoma de México, working with the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, applied this strategy to three Aspergillus targets: the section Fumigati (which includes A. fumigatus and its cryptic sister species), A. flavus, and A. niger. Using 80 Aspergillus isolates from their Molecular Mycology Laboratory collection—spanning Mexico, Argentina, France, Peru, and Cuba—plus reference strains from the American Type Culture Collection, they screened RAPD-PCR patterns generated with three arbitrary primers: OPF-01, P54, and 1253. Of 34 polymorphic patterns, only these three primers yielded bands that were consistently present across all isolates of their respective targets and absent from everything else.

The team excised the specific bands from agarose gels, purified them, cloned them into plasmid vectors, and sequenced them. BLAST analysis against GenBank confirmed their specificity: the 1000-base-pair fragment from OPF-01 recognized only section Fumigati sequences with 100 percent coverage and similarity; the 400-base-pair P54 fragment matched only A. flavus at 97.94 percent similarity; and the 1000-base-pair 1253 fragment aligned exclusively with A. niger at 98.18 percent similarity. From these sequences, the researchers designed primer pairs using the Primer3 program, adhering to strict design criteria—18 to 25 nucleotides in length, 40 to 60 percent GC content, and melting temperatures between 55 and 65 degrees Celsius—to prevent primer dimers, secondary structures, and nonspecific hybridization.

Three SCAR markers emerged: AfOPF-01₁₈₀, which amplifies a 180-base-pair band specific to section Fumigati; AfP54_193.1, which produces a 193-base-pair band recognizing A. flavus; and An1253₂₂₀, which yields a 220-base-pair band in A. niger and, notably, its close relative A. luchuensis. Specificity testing against a panel that included other Aspergillus sections—Flavi, Nigri, and species such as A. tamarii, A. tubingensis, A. lentulus, and A. hiratsukae—as well as unrelated medically important genera like Candida, Histoplasma, Coccidioides, and Sporothrix, confirmed that the markers did not cross-react. Sensitivity assays using serial dilutions of genomic DNA revealed a limit of detection of 0.005 nanograms per microliter for all three markers—impressively low for an endpoint PCR approach.

The real test came with clinical samples. The team analyzed 51 galactomannan-positive bronchoalveolar lavage (BAL) samples from patients evaluated for aspergillosis at the Mexican respiratory institute. Because fungal DNA concentrations in BAL fluid are often vanishingly small, the researchers performed a re-amplification step after the initial PCR. The AfOPF-01₁₈₀ marker detected section Fumigati DNA in 19 of 51 samples—37.25 percent positivity. AfP54_193.1 identified A. flavus in 3 of 51 samples, or 5.88 percent. An1253₂₂₀, despite its analytical specificity, produced no positive results in the clinical cohort—a silence the authors attribute to possible low fungal load, PCR inhibitors in the sample matrix, non-homogeneous distribution of the microorganism, or sample degradation during storage.

The implications are considerable. Section-level identification matters because cryptic species within section Fumigati—A. lentulus, A. udagawae, A. felis, A. hiratsukae, A. viridinutans—are morphologically indistinguishable from A. fumigatus yet differ in antifungal susceptibility, sometimes dramatically. The galactomannan test, the current clinical workhorse, identifies only the genus level, offering no species resolution. The AfOPF-01₁₈₀ marker, by contrast, provides section-level specificity that could guide empiric therapy while species-level markers like AfP54_193.1 refine treatment decisions further. The markers were also designed from autochthonous isolates, a point of epidemiological relevance given the high genetic variability observed across Aspergillus species, particularly A. fumigatus.

Still, the authors are careful to frame this as a preliminary feasibility study, not a validated diagnostic. The cohort was small and homogeneous, drawn exclusively from galactomannan-positive samples; there was no internal amplification control for the BAL specimens; the limit of detection was determined subjectively by band presence or absence; and the study lacked data on aspergillosis classification in the patients whose samples were used. Concordance with culture-based identification could not be assessed because diagnosis rested solely on galactomannan detection. Cross-reactivity with Aspergillus sections not represented in the specificity panel remains a theoretical concern. The researchers call for prospective, multicenter validation across diverse populations and sample types before the markers can be considered clinically deployable. Yet the core message is clear: SCAR technology, long used in plant pathology, herbal drug authentication, and food microbiology, may finally have a foothold in the diagnosis of one of humanity’s most underappreciated fungal threats—a tool that is low-cost, rapid, and interpretable with nothing more than a thermocycler and an agarose gel.

Subject of Research: Preliminary clinical evaluation of SCAR-type molecular markers for the identification of the section Fumigati, A. flavus, and A. niger in bronchoalveolar lavage samples

Article Title: Preliminary clinical evaluation of SCAR-type molecular markers for the identification of the section Fumigati, A. flavus, and A. niger in bronchoalveolar lavage samples

Article References: Preliminary clinical evaluation of SCAR-type molecular markers for the identification of the section Fumigati, A. flavus, and A. niger in bronchoalveolar lavage samples. (n.d.). https://doi.org/10.3389/fitd.2026.1892022

Image Credits: AI Generated

DOI: 10.3389/fitd.2026.1892022

Keywords: aspergillosis, Aspergillus, SCAR markers, molecular diagnostics, PCR, fungal disease, bronchoalveolar lavage, infectious disease, Preliminary, clinical, evaluation, SCAR-type